Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary intervention (PCI) will allow for flexibility in length of stay while ensuring patient safety. The guidelines were published in early-view online in Catheterization and Cardiovascular Interventions, the official journal of the Society for Cardiovascular Angiography and Interventions (SCAI).

May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used ...

May 14, 2018 – A new study examines the effectiveness of 3-D printing technology and computer modeling to predict ...

May 14, 2018 — A significant update to the PROGRESS-CTO (PROspective Global Registry for the Study of Chronic Total ...

Ancora Heart Inc. announced the expansion of the company’s U.S. feasibility study to evaluate the investigational AccuCinch Ventricular Repair System designed for the treatment of heart failure and functional mitral regurgitation (FMR). Ancora has received approval from the U.S. Food and Drug Administration (FDA) to enroll a second group of subjects and expand to 15 heart centers across the United States.

Results of the FlowTriever Pulmonary Embolectomy (FLARE) study were presented as late-breaking clinical science at the Society for Cardiovascular Angiography and Interventions (SCAI) 2018 Scientific Sessions, April 25-28 in San Diego. The FLARE study is a prospective, single-arm multicenter trial designed to evaluate the safety and efficacy of the Flowtriever system (Inari Medical, Irvine, Calif.) in patients with acute pulmonary embolism (PE). It is the first trial to treat pulmonary embolism without using thrombolytics, the use of drugs to break up or dissolve blood clots that can lead to bleeding complications.